Altimmune to Present Pemvidutide Clinical Data at EASL 2024
Altimmune, Inc., a clinical-stage biopharmaceutical company, has revealed new data showcasing the anti-inflammatory and anti-fibrotic capabilities of pemvidutide. This investigational treatment targets metabolic dysfunction-associated steatotic liver disease (MASLD) and will be discussed at the EASL International Liver Congress™ 2024 in Milan, Italy. Pemvidutide is a novel peptide-based GLP-1/glucagon dual receptor agonist aimed at treating obesity and metabolic dysfunction-associated steatohepatitis (MASH).
Three key presentations will highlight these findings. The first, titled "Pemvidutide, a glucagon-like peptide 1/glucagon dual receptor agonist, improves metabolic dysfunction-associated steatohepatitis activity and fibrosis in a clinical quantitative systems pharmacology model" (abstract #2881), will be presented by Dr. Sarah Browne, Vice President of Clinical Development at Altimmune. This session will take place on Wednesday, June 5, 2024, at 8:30 am CEST.
The second presentation, "Plasma lipidomic profiling of subjects with overweight or obesity following treatment with the glucagon-like peptide 1/glucagon dual receptor agonist pemvidutide: an investigation of lipid signatures associated with metabolic dysfunction-associated steatohepatitis" (abstract #2985), will be delivered by Dr. Scot Roberts, Chief Scientific Officer at Altimmune, at the same date and time.
The third presentation, "Pemvidutide treatment is associated with improvement in noninvasive tests indicating greater likelihood of histologic response in subjects with metabolic dysfunction-associated steatotic liver disease: a 24-week, randomized, double-blind, placebo-controlled trial" (abstract #3002), will be given by Dr. Shaheen Tomah, Associate Director of Clinical Development at Altimmune, also on June 5, 2024, at 8:30 am CEST. Attendees of the congress will have the opportunity to view these posters throughout the event, with copies available on the Altimmune website.
Pemvidutide, the subject of these studies, functions by activating both GLP-1 and glucagon receptors. This dual activation is intended to replicate the beneficial effects of diet and exercise, with GLP-1 reducing appetite and glucagon enhancing energy expenditure. Additionally, glucagon directly impacts liver fat metabolism, contributing to significant reductions in liver fat and serum lipids. Clinical trials have demonstrated that once-weekly pemvidutide leads to notable weight loss and decreases in triglycerides, LDL cholesterol, liver fat, and blood pressure. Pemvidutide has received Fast Track designation from the U.S. FDA for treating MASH and has recently completed the MOMENTUM Phase 2 obesity trial. It is currently being evaluated in the ongoing IMPACT Phase 2b MASH trial.
Altimmune, the company behind this innovative treatment, specializes in developing next-generation peptide-based therapeutics. The focus of their current research is on creating effective treatments for obesity and MASH, with pemvidutide being a key candidate.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
